On June 16, 2026, Nexalin Technology, Inc. adopted Second Amended and Restated Bylaws. Key changes include lowering the stockholder meeting quorum from a majority to one-third of outstanding voting power and replacing the prohibition on stockholder action by written consent with new procedures for action by consent without a meeting. The bylaws also revise advance notice procedures for director nominations to address Rule 14a-19, update board structure and director removal provisions, and establish a forum selection clause designating Delaware courts for internal corporate claims. The company operates in the medical technology industry, developing non-invasive therapeutic devices.
